Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 11, 2011

Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine

  • Marisol López , Pedro Dorado , Nancy Monroy , María Elisa Alonso , Helgi Jung-Cook , Esther Machín , Eva Peñas-Lledó and Adrián Llerena EMAIL logo

Abstract

Patients treated with antiepileptic drugs can exhibit large interindividual variability in clinical efficacy or adverse effects. This could be partially due to genetic variants in genes coding for proteins that function as drug metabolizing enzymes, drug transporters or drug targets. The purpose of this article is to provide an overview of the current knowledge on the pharmacogenetics of two commonly prescribed antiepileptic drugs with similar mechanisms of action; phenytoin (PHT) and lamotrigine (LTG). These two drugs have been selected in order to model the pharmacogenetics of Phase I and Phase II metabolism for PHT and LTG, respectively. In light of the present evidence, patients treated with PHT could benefit from CYP2C9 and CYP2C19 genotyping/phenotyping. For those under treatment with LTG, UGT1A4 and UGT2B7 genotyping might be of clinical use and could contribute to the interindividual variability in LTG concentration to dose ratio in epileptic patients.


Corresponding authors: Pedro Dorado/Adrián Llerena, CICAB Clinical Research Centre, Extremadura University Hospital and Medical School, Servicio Extremeño de Salud, Badajoz, Spain

Received: 2011-2-24
Accepted: 2011-4-5
Published Online: 2011-05-11
Published in Print: 2011-05-01

©2011 by Walter de Gruyter Berlin New York

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/dmdi.2011.008/html
Scroll to top button